Pelosi's drug pricing bill faces progressive scrutiny

Some Dems fear that the reform bill will fall substantially short of their goals to cut drug prices for Americans.

By Marlene Satter | September 19, 2019 at 11:26 AM

Blister pack with dollars instead of pills One sticking point of the bill is the lack of provision that's been key for progressives—that federal officials be authorized to negotiate prices directly on at least 250 drugs. (Photo: Shutterstock)

It was negotiated behind closed doors, with progressive Democrats shut out of the process, so it's an open question how they'll react when House Speaker Nancy Pelosi, D-CA, unveils her drug pricing bill.

Politico reports that the agreement has left progressives in the dark; they fear that it will fall substantially short of their goals to cut drug prices for Americans. Pelosi's goal is to get the legislation passed by Thanksgiving, but with details scarce it's tough to predict how successful that will be.

 

Related: Overall costs for generic drugs decline, but consumers not seeing the savings

So what does the bill actually do? Although it could still change in committee, at present it allows the government to tax drugmakers who refuse to negotiate on drug prices, as well as tying the maximum price of those drugs to what's paid for them in other countries.

In addition, it caps what seniors have to pay out of pocket for their drugs under Medicare Part D at $2,000.

Most of the discussion around the legislation this week appeared to focus on technical aspects of the bill rather than substance, and those who have seen it appear to believe it will succeed. However, a number of legislators aren't happy about the process—the close-door meetings and the push for speed.

And the bill does not include a provision that's been key for progressives—that federal officials be authorized to negotiate prices directly on at least 250 drugs. Instead, it set the bar far lower, at 25, with a maximum of 250 per year. Neither does it allow for immediate limits on the price of newly launched medicines, which was another progressive requirement.

Progressives have already registered their objections to the fact that the bill waters down other provisions without even attempting passage; indeed, the Congressional Progressive Caucus has characterized it as Democrats "negotiate[ing] against themselves" in an attempt to woo Republican support.

Politico adds that five CPC members, led by co-chairs Mark Pocan, D-WI, and Pramila Jayapal, D-WA, wrote a public letter to Pelosi in August warning that CPC members might not back the bill if it does not meet their standards.

"Our position has not changed a millimeter," Pocan is quoted saying in the report, adding, "I don't think anyone wants to go back home and say we're negotiating for 25 drugs. It's gotta be something more substantive."

 

NOT FOR REPRINT

© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Marlene Satter

Marlene Y. Satter has worked in and written about the financial industry for decades.

By Allison Bell | April 22, 2025

Pharmacists say they should be able to use standard billing codes to get reimbursement for providing patient care.

Pharmacists want employers to pay them for providing flu shots and screening tests

By Kristen Smithberg | April 22, 2025

Similar ownership provisions are under consideration in Indiana, New York, Texas and Vermont. 

Arkansas law bans PBM ownership of pharmacies

By Allison Bell | April 22, 2025

A ruling in favor of keeping the current task force structure in place could give Kennedy firm control over the task force.

Supreme Court may back Affordable Care Act preventive services selection task force
The Insider's Guide to Reliable Provider Directories for Brokerages and FMOs link

Guide

Sponsored by Zelis

The accuracy of your provider directories is vital to shaping your success. The guide provides actionable insights and best practices for ensuring the data you rely on is precise and trustworthy.

How One Employer Helped 1 in 3 Employees Improve Blood Pressure link

Case Study

Sponsored by Labcorp

High blood pressure affects nearly half of U.S. adults, increasing the risk of heart disease and stroke. This case study explores how an employer-sponsored wellness program helped approximately 1 in 3 employees improve their blood pressure risk level.

Reducing Employee Onboarding Time and Solving Staffing Challenges link

Case Study

Sponsored by Labcorp

Long onboarding times and staffing shortages create costly delays. Discover how one large healthcare system streamlined its hiring process, reducing onboarding time from weeks to days while improving the candidate experience and freeing up internal staff.